A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Oncology
Most Recent Events
- 06 May 2020 New trial record